@article{oai:nagasaki-u.repo.nii.ac.jp:00006883,
 author = {Nakamura, Hideki and Ueki, Yukitaka and Saito, Shigeki and Horai, Yoshiro and Suzuki, Takahisa and Naoe, Tomoki and Eguchi, Katsumi and Kawakami, Atsushi},
 issue = {17},
 journal = {Internal Medicine},
 month = {Sep},
 note = {Tocilizumab (TCZ) was administered from 2004 to 2008 in a 52-year-old woman with rheumatoid arthritis (RA) refractory to methotrexate (MTX) as a clinical trial. TCZ therapy with MTX was resumed in March 2009 due to exacerbation of RA. The patient was an human T-lymphotropic virus type I (HTLV-I) carrier, and, in April 2011, a peripheral blood smear showed many atypical lymphocytes, thus leading to a diagnosis of adult T-cell leukemia (ATL). Complete remission of ATL was achieved with a standard therapeutic regimen., Internal Medicine, 52(17), pp.1983-1986; 2013},
 pages = {1983--1986},
 title = {Development of Adult T-cell Leukemia in a Patient with Rheumatoid Arthritis Treated with Tocilizumab},
 volume = {52},
 year = {2013}
}